Collegium Pharmaceutical issues 2026 financial guidance

Collegium Pharmaceutical Inc. (NASDAQ: COLL) announced financial guidance for 2026, projecting product revenues between $805 million and $825 million. The company expects net revenue from its ADHD medication Jornay PM to range from $190 million to $200 million.

The pharmaceutical company forecasts adjusted EBITDA between $455 million and $475 million for 2026. Collegium raised its 2025 guidance in November to net revenue of $775 million to $785 million with adjusted EBITDA of $460 million to $470 million.

In December, Collegium completed a $980 million syndicated credit facility, which included repaying $581 million of its previous term loan. The new facility consists of a $580 million senior secured term loan, $300 million delayed draw term loan, and $100 million revolving credit facility.

The company entered supply agreements with Hikma Pharmaceuticals USA Inc. for authorized generic versions of Nucynta and Nucynta ER. Hikma expects to launch the authorized generic version of Nucynta ER in the first quarter of 2026, with Nucynta following in December 2026 or upon third-party generic launch. Collegium will receive a share of net profits from these authorized generic products.

"The outstanding performance of Jornay PM, along with sustained revenue growth across our pain portfolio, has put us in a strong financial position," said CEO Vikram Karnani in a statement.

CFO Colleen Tupper indicated that 2026 revenue growth will be driven largely by increasing Jornay PM sales. The company plans to balance debt reduction, share repurchases, and business development opportunities in its capital deployment strategy.

You May Also Be Interested In

• Roadzen posts 42% revenue jump in Q4 as annual sales hit $55M
• Bed Bath & Beyond outlines plan to connect housing services
• Hadron Energy hires DLA Piper for nuclear reactor policy push